EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network homepage

Menu

Members

Fabio Malavasi

Name of the laboratory

Laboratory of Immunogenetics
Dept of Genetics, Biology and Biochemistry
University of Torino Medical School
Via Santena, 19
10126 Torino

Members of the laboratory

Members: Laboratory of Immunogenetics
Director
Unit Leader
Alberto Horenstein alberto.horenstein@unito.it
Ph.D.
Erika Ortolan
Tiziana Vaisitti
Ph.D. Student
Paola Bovino
Nicola Lo Buono
Giulia Nacci
Mariama Elbaroudi
Rossella Parrotta
Gianluca Zaccarello
Visiting Scientist
Alona Inzhutova
Semra Aydin
Technician
Rodica Markus
Francesca Cottino
Katiuscia Gizzi

Techniques available

  • Production of murine monoclonal antibodies
  • Production polyclonal antibodies
  • Production of human monoclonal antibodies
  • Purification of mAbs at a clinical grade

Publications (2016-present)

  • F. Morandi, D. Marimpietri, A. L. Horenstein, M. Bolzoni, D. Toscani, F. Costa, B. Castella, A. C. Faini, M. Massaia, V. Pistoia,N. Giuliani, and F. Malavasi. Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NADC. OncoImmunology (2018, in press) (I.F. 7.719)
  • A. Chong, F. Malavasi, S. Israel, C. Chuen Khor, V. Bing Yap, M. Monakhov, S. Hong Chew, P. San Lai and R. P. Ebstein. ADP ribosyl-cyclases (CD38/CD157), social skills and friendship. Psychoneuroendocrinology 78: 185-192, 2017 (I.F. 4.704)
  • A. Chillemi, V. Quarona, L. Antonioli, D. Ferrari, A.L. Horenstein and F. Malavasi. Roles and modalities of ectonucleotidase in remodeling the multiple myeloma niche. Frontiers in Immunology 8: 305, 2017 (I.F. 5.695)
  • A.L. Horenstein, V. Quarona, F. Morandi, A. Chillemi and F. Malavasi. Adenosine in the bone marrow myeloma niche: immune checkpoint and key player in the progression of myeloma disease. Journal of Cell Signaling (2017, in press)
  • G. Mesiano, R. Zini, G. Montagner, N. Bianchi, R. Manfredini, A. Chillemi, M. Aglietta, G. Grignani, I. Lampronti, E. Fiorino, F. Malavasi, D. Sangiolo, R. Gambari and D. Ferrari. Analytic and dynamic secretory profile of patient-derived cytokine-induced killer cells. Molecular Medicine 9;23, 2017 (I.F. 3.530)
  • L. D’Abundo, E. Callegari, A. Bresin, A. Chillemi, B.K. Elamin, P. Guerriero, X. Huang, E. Saccenti, E.M.A.A. Hussein, F. Casciano, P. Secchiero, G. Zauli, G. A. Calin, G. Russo, L.J. Lee, C.M. Croce, G. Marcucci, S. Sabbioni, F. Malavasi and M. Negrini. Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. Oncogene 36(47): 6617-6626, 2017 (I. F. 7.519)
  • I. Schiavoni, C. Scagnolari, A.L. Horenstein, P. Leone, A. Pierangeli, F. Malavasi, C. Ausiello and G. Fedele. CD38 modulates respiratory syncytial virus-driven pro-inflammatory processes in human monocyte-derived dendritic cells. Immunology (2017, in press) (I.F. 3.701)
  • W. Fumey, J. Koenigsdorf, V. Kunick, S. Menzel, K. Schütze, M. Unger, L. Schriewer, F. Haag, G. Adam, A. Oberle, M. Binder, R. Fliegert, A. Guse, YJ Zhao, H. Cheung Lee, F. Malavasi, F. Goldbaum, R. van Hegelsom, C. Stortelers, P. Bannas, F. Koch-Nolte. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo. Scientific Report 7(1):14289, 2017
  • Marshall D., Chillemi A., Malavasi F. and Prudent J. Precision Targeting of Ion Channel Blocker for the Treatment of AML. Blood 130: 5203, 2017 (I.F. 13.164)
  • F. Morandi, A. L. Horenstein, R. Rizzo and F. Malavasi. The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases Mediators of Inflammation
  • N.W.C.J. van de Donk, P.G. Richardson and F. Malavasi. CD38 antibodies in multiple myeloma: back to the future. Blood (2017, in press) (I.F. 13.164)
  • M. Gregori, A. Orlando. F. Re, S. Sesana, L. Nardo, D. Salerno, F. Mantegazza, E. Salvati, A. Zito, F. Malavasi, M. Masserini and E. Cazzaniga. Novel anti-transferrin receptor antibodies improve the blood-brain barrier crossing efficacy of immunoliposomes. Journal of Pharmaceutical Sciences 105 (1): 276-283, 2016 (I.F. 2.590)
  • N.W.C.J.van de Donk, P. Moreau, T. Plesner, A. Palumbo, F. Gay, J.P. Laubach, F. Malavasi, H.Avet-Loiseau, M.V. Mateos, P. Sonneveld, H.M. Lokhorst, P. G. Richardson. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127: 681-695, 2016 (I.F. 13.164)
  • A. Zito, C. Bromuro, G. Mandili, P. Chiani, A.L. Horenstein, F. Malavasi, R. Cauda, A. Cassone and A. Torosantucci. A murine, bispecific monoclonal antobody simultaneously recognizing β-glucan and MP65 determinants in candida species. PLOS One 11(2): e 0148714, 2016 (I.F. 3.234)
  • D. J. Marshall, S. Harried, J. Murphy, C. Hall, M. S. Shekhani, C. Pain, C. Lyons, A. Chillemi, F. Malavasi, H. L. Pearce, J. S. Thorson and J. R. Prudent. Extracellular antibody drug conjugates exploiting the proximity of two proteins. Molecular Therapy 24(10): 1760-1770, 2016 (I.F. 6.225)
  • L. Antonioli, C. Blandizzi, F. Malavasi, D. Ferrari and G. Haskό. Anti-CD73 immunotherapy: a viable way for reprogramming the tumor microenvironment. Oncoimmunology Vol. 5, NO 9, e1216292 (3 pages), 2016 (I.F. 7.644)
  • A.L. Horenstein, V. Quarona, D. Toscani, F. Costa, A. Chillemi, V. Pistoia, N. Giuliani and F. Malavasi. Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma. Molecular Medicine 13: 22, 2016 (I.F. 3.53)
  • A.L. Horenstein, A. Chillemi, V. Quarona, A. Zito, V. Mariani, A. C. Faini, F. Morandi, I. Roato, C. Ausiello and F. Malavasi. Antibody mimicry, receptors and clinical applications. Human Antibodies, 2016
  • D. Ferrari, F. Malavasi and L. Antonioli. A purinergic Trail for metastases. Trends in Pharmacological Sciences 38(3): 277-290, 2016 (I.F. 11.840)
  • M. Benkisser-Petersen, M. Buchner, A. Dörffel, M. Dühren-von-Minden, R. Claus, K. Kläsener, K. Leberecht, M. Burger, C. Dierks, H. Jumaa, F. Malavasi, M. Reth, H. Veelken, J. Duyster, K. Zirlik. Spleen tyrosine kinase involved in the CD38 signal transduction pathway in chronic lymphocytic leukemia. PLOS One 11(12): e0169159, 2016 (I.F. 3.057)
  • F. Malavasi, A. Chillemi, B. Castella, I. Schiavoni, D. Incarnato, S. Oliva & A.L. Horenstein. CD38 and antibody therapy: what can basic science add?. Blood 128: SCI-36, 2016 [abstract]